CYP2D6,CYP2C19,CYP2B6,SLC6A4,HTR2A genotypes and serotonin reuptake inhibitor antidepressants:interpretation of the 2023 CPIC guideline
ZHOU Changkai
YU Hongxia
CAO Mingchen
SHI Yunyan
LIU Donghua
JI Hongyan
XING Xiaomin
WANG Xinyi
LI Jing
JING Fanbo
Abstract：The Clinical Pharmacogenetics Implementation Consortium(CPIC)updated and expanded the 2015 guideline for CYP2D6 and CYP2C19 genotypes and selective serotonin reuptake inhibitors(SSRIs)in 2023,adding CYP2B6,SLC6A4,HTR2A,SNRIs,and 5-HT modulators with SSRI-like activity in the sections related to genotype and drugs.The new guideline also updated the application recommendations for serotonin reuptake inhibitors based on gene polymorphism.This article interprets the relevant content of the guideline,in order to provide reference for the individualized treatment of 5-HT reuptake inhibitors in China.
Keywords：GuidelineGenetic polymorphismSerotonin reuptake inhibitorAntidepressantInterpretation
Publication Date：2024-05-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：9( 495-503 )